|
Death in early adulthood
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of vision
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Cerebral cortical atrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Gait Disturbance, CTCAE
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Agitation, CTCAE 5.0
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Memory Impairment, CTCAE 5.0
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Decreased level of GABA in serum
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
CTD_human |
"How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the ""LEARn"" model (latent early-life associated regulation) may explain the triggering of AD."
|
17430250 |
2007 |
|
Alzheimer Disease, Early Onset
|
0.500 |
Biomarker
|
disease |
CTD_human |
"How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the ""LEARn"" model (latent early-life associated regulation) may explain the triggering of AD."
|
17430250 |
2007 |
|
Presenile dementia
|
0.400 |
Biomarker
|
disease |
CTD_human |
"How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the ""LEARn"" model (latent early-life associated regulation) may explain the triggering of AD."
|
17430250 |
2007 |
|
Familial Alzheimer Disease (FAD)
|
0.400 |
Biomarker
|
disease |
CTD_human |
"How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the ""LEARn"" model (latent early-life associated regulation) may explain the triggering of AD."
|
17430250 |
2007 |
|
Alzheimer Disease, Late Onset
|
0.400 |
Biomarker
|
disease |
CTD_human |
"How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the ""LEARn"" model (latent early-life associated regulation) may explain the triggering of AD."
|
17430250 |
2007 |
|
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
"How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the ""LEARn"" model (latent early-life associated regulation) may explain the triggering of AD."
|
17430250 |
2007 |
|
Alzheimer's Disease, Focal Onset
|
0.300 |
Biomarker
|
disease |
CTD_human |
"How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the ""LEARn"" model (latent early-life associated regulation) may explain the triggering of AD."
|
17430250 |
2007 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b>: AD: Alzheimer disease; APP: amyloid beta precursor protein; MAPT: microtubule associated protein tau; MTOR: mechanistic target of rapamycin kinase; MTORC1: mechanistic target of rapamycin kinase complex 1.
|
31066320 |
2019 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> The beta-amyloid peptide (Aβ) involved in Alzheimer's disease (AD) has been described to associate/aggregate on the cell surface disrupting the membrane through pore formation and breakage.
|
30123122 |
2018 |
|
Impaired cognition
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusion</b>: These results suggest that UTI inhibits neuronal apoptosis in rat brain by attenuating increased expression of Aβ<sub>42</sub> and inflammatory cytokines, which may contribute to its alleviation of isoflurane-induced cognitive dysfunction in rats.
|
31311447 |
2019 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> ICA shows the neuroprotective effects via modulating the CD4<sup>+</sup> T lymphocyte-related immuno-inflammatory responses in APP/PS1 mice and may be a promising drug against AD progression.
|
31190768 |
2019 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
<b>Materials and methods:</b> Sixty APP/PS1 transgenic mice were randomly divided into an AD model group, a T10-treated group and a T4-treated group (<i>n</i> = 20); 20 wild-type littermates served as the control group.
|
31311385 |
2019 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
<b>Methods</b>: The AD animal model (APP/PS1 transgenic mice) and KIBRA knockout (KIBRA KO) mice were used to investigate pathophysiological changes of KIBRA <i>in vivo</i>.
|
31031595 |
2019 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> In APP/PS1 transgenic mice and Aβ treated microglia, the interaction between HSP90 and PPARγ were analyzed by western blot.
|
30128052 |
2018 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> Thirty seven-month-old APP/PS1 mice were randomly divided into AD Model group (AD group), medicine group (M group) and EA group, C57BL/6 mice were used for Normal control group (N group), <i>n</i> = 10 in each group.
|
28174534 |
2017 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
<b>Results</b>: The oral treatment of AD brain extract or normal brain extract neither aggravated nor mitigated the Aβ load, glial activation or the abnormal behaviors in recipient Amyloid precursor protein/presenilin 1 (APP/PS1) mice.
|
30108498 |
2018 |
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
(-)-Epigallocatechin gallate (EGCG) effectively reduces the cytotoxicity of the Alzheimer's disease β-amyloid peptide (Aβ) by remodeling seeding-competent Aβ oligomers into off-pathway seeding-incompetent Aβ assemblies.
|
28841302 |
2017 |
|
Infarction, Middle Cerebral Artery
|
0.200 |
Therapeutic
|
disease |
RGD |
(-)-Phenserine inhibits neuronal apoptosis following ischemia/reperfusion injury.
|
28963051 |
2017 |